Ra Capital Management, L.p. bought $755k of CLYM
director, owner at Eliem Therapeutics, Inc.. 314,561 shares at an average of $2.40, traded Dec 11, 2025, filed Dec 15, 2025.
Score components
- +15RoleDirector
- +22Trade size$755k at market
- +3Relative to holdingsHoldings up 10%
- +4Price context26% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- -5Track recordMedian 6-month excess return -38% over 3 past buys
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +3.9%, 3m +87.1%, 6m +201.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-25-000616, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 11, 2025 | DDisposition to issuer Common Stockindirect: See footnotes | -20,440,000 | $0.00 | $0 | 3,081,757 | Dec 15, 2025 |
| Dec 11, 2025 | POpen-market purchase Common Stockindirect: See footnotes | +213,099 | $2.18 | $465k | 3,294,856 | Dec 15, 2025 |
| Dec 12, 2025 | POpen-market purchase Common Stockindirect: See footnotes | +101,462 | $2.86 | $290k | 3,396,318 | Dec 15, 2025 |
| Dec 11, 2025 | AGrant or award Pre-Funded Warrants (Right to Buy)derivativeindirect: See footnotes | +20,440,000 | - | - | 20,440,000 | Dec 15, 2025 |
Related signals
Other insiders at Eliem Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Eliem Therapeutics, Inc. | Stephen Basil Thomas director | $1.4M 100,000 shares | -18% | |
| 16Weak | Eliem Therapeutics, Inc. | Aoife Brennan President and CEO | $407k 30,902 shares | -26% | |
| 15Weak | Eliem Therapeutics, Inc. | Stephen Basil Thomas director | $350k 50,000 shares | -24% | |
| 23Weak | Eliem Therapeutics, Inc. | Stephen Basil Thomas director | $529k 100,000 shares | -33% | |
| 14Weak | CLYMbuy Eliem Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $25k 7,111 shares | +0% | |
| 13Weak | Eliem Therapeutics, Inc. | Aoife Brennan President and CEO | $25k 20,618 shares | -30% | |
| 0Weak | Eliem Therapeutics, Inc. | Emily Pimblett SVP, Finance & CAO | $1,540 1,242 shares | -6% | |
| 0Weak | Eliem Therapeutics, Inc. | Emily Pimblett SVP, Finance & CAO | $1,571 1,199 shares | -7% | |
| 0Weak | Eliem Therapeutics, Inc. | Emily Pimblett CHIEF ACCOUNTING OFFICER | $2,495 1,235 shares | -10% | |
| 0Weak | Eliem Therapeutics, Inc. | Emily Pimblett CHIEF ACCOUNTING OFFICER | $9,741 1,191 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.